As PTGS2 inhibitors are considered to be a potential risk factor for bone healing [24], we suspect that the down-regulation of PTGS2 in SAPHO syndrome may contribute to the osteoarticular lesions in patients. This evidence concerns the gene PTGS2 and SAPHO syndrome.